Ben Inker: What Looks Cheap and Dear in Today’s Market

Episode Summary

Executive Summary: Ben Inker, head of asset allocation at GMO, discusses the current investment landscape, highlighting a 'spoiled for choice' environment where both equities and bonds offer attractive opportunities. He explains the 'quality anomaly,' where high-quality stocks persistently outperform despite lower risk, and details GMO's bullish outlook on value equities, particularly Japanese small-cap value, while remaining cautious on U.S. mega-cap growth stocks. Inker also addresses the role of interest rates, the concentration of the U.S. market, and the evolving approach to ESG investing.

Main Topics: The Quality Anomaly and GMO's QLTY ETF (Priority: 5/5): Inker explains the 'weird' persistence of the quality factor, where high-quality companies outperform despite lower risk, contradicting efficient market theory. He discusses GMO's first ETF, QLTY, which focuses on U.S. quality stocks, and notes that quality works globally but is most pronounced in the U.S. Current Market Outlook: 'Spoiled for Choice' (Priority: 5/5): Inker describes the current environment as offering compelling opportunities across asset classes, with bonds yielding attractive returns for the first time in years and value equities trading at significant discounts. He emphasizes that investors are well-compensated for taking risk. Value vs. Growth and the 'Rebalancing' Effect (Priority: 4/5): Inker argues that value's outperformance is driven by 'rebalancing'—stocks moving between value and growth universes. With a wide valuation gap, value stocks that graduate to growth generate large returns, while growth stocks that disappoint (growth traps) suffer. He sees this dynamic favoring value. U.S. Market Concentration and the Magnificent Seven (Priority: 4/5): Inker compares the current concentration in U.S. mega-cap stocks to the Nifty 50 era of the early 1970s. He notes that while these companies have delivered strong growth, their high valuations and potential for regulatory or competitive challenges make future outperformance uncertain. Bullish on Japanese Equities, Especially Small-Cap Value (Priority: 4/5): Inker highlights Japan's improved return on capital, cheap yen, and government support for corporate reforms. He favors Japanese small-cap value stocks due to their net cash positions, low valuations, and local cost advantages from the weak yen. China: Not Uninvestable, but Less Preferred (Priority: 3/5): Inker explains that GMO reduced its China exposure in 2020-2021 due to high valuations and geopolitical risks. While China is no longer overvalued, he prefers other emerging markets for their larger value discounts and more balanced risks. ESG Investing: Risk, Quality, and Realistic Expectations (Priority: 3/5): Inker views ESG as a cousin of quality, used to assess risk. He criticizes oversimplified narratives that promise easy outperformance and notes that excluding sectors can be a personal choice but may not significantly impact returns. He advocates for a nuanced approach, such as GMO's climate change strategy.

Key Arguments: High-quality stocks have persistently outperformed despite lower risk, which is a 'weird' anomaly that contradicts efficient market theory. The current investment environment is attractive because both equities and bonds offer higher expected returns than in recent years, with cash yielding over 5%. Value stocks are poised to outperform growth due to the 'rebalancing' effect: the wide valuation gap means value stocks that improve will see large gains, while growth stocks that disappoint will suffer. U.S. market concentration in the Magnificent Seven is reminiscent of the Nifty 50 era, and these stocks face headwinds from high valuations and potential regulatory challenges. Japan offers a compelling opportunity due to improved corporate profitability, a cheap yen, and government-led reforms, with small-cap value stocks being particularly attractive. China is not uninvestable, but GMO prefers other emerging markets due to better value opportunities and more diversified geopolitical risks. ESG should be integrated as a risk factor, not a guarantee of outperformance, and investors should avoid simplistic narratives about its benefits.

Data Points: Top 7 U.S. stocks as % of S&P 500: ~29% - Concentration level comparable to the Nifty 50 era in the early 1970s. Magnificent Seven average return in 2023: ~100% - Contrasted with the rest of the U.S. market returning ~3%. Japanese operating margins since 2013: Doubled - Improvement since Prime Minister Abe's policies, indicating better corporate profitability. Yen valuation: Cheapest since 1971 - Provides a tailwind for Japanese exporters, especially small caps with local costs. Cash yield in 2023: ~5% - Highest in 20 years, making cash and hedged strategies more attractive. China's weight in MSCI Emerging Markets Index: ~40% - At its peak, making it difficult to diversify geopolitical risks within emerging markets.

Pivotal Quotes: "It is never enough to look at the returns of an asset, you need to understand how those returns were generated." — Ben Inker: Inker credits Jeremy Grantham with this lesson, which underpins GMO's analytical approach. "The one group of stocks that really deserves to underperform in the long run... the weird thing, the quality anomaly, is that they don't underperform. In fact, they have outperformed." — Ben Inker: Explaining the persistent outperformance of high-quality stocks despite lower risk. "The exciting thing for investors is whether you're looking to buy an equity portfolio, a fixed-income portfolio, or a diversified portfolio across assets. The outlook looks pretty good." — Ben Inker: Summarizing the current 'spoiled for choice' environment with attractive opportunities across asset classes.

Implications: Investors should consider increasing exposure to value equities, especially in Japan and other non-U.S. markets, while being cautious on U.S. mega-cap growth. Bonds and cash now offer meaningful yields, improving portfolio construction options. ESG integration should focus on risk assessment rather than expecting automatic outperformance.